Development of a novel engineered antibody targeting human CD123 |
| |
Authors: | Shima Moradi-Kalbolandi Mahdi Habibi-Anbouhi Majid Golkar Mahdi Behdani Gashin Rezaei Leila Ghazizadeh Mohsen Abolhassani Mohammad Ali Shokrgozar |
| |
Institution: | 1. National Cell Bank of Iran, Pasteur Institute of Iran, Tehran, 13164, Iran;2. Parasitology Department, Pasteur Institute of Iran, Tehran, 13164, Iran;3. Biotechnology Research Center, Venom & Biotherapeutics Molecules Lab, Pasteur Institute of Iran, Tehran, 13164, Iran;4. Immunology Department, Hybridoma Lab, Pasteur Institute of Iran, Tehran, 13164, Iran |
| |
Abstract: | Antibody engineering involves a range of custom modifications of immunoglobulins to improve their affinity, valency, and pharmacokinetics, ensuring a better target therapy achievement. A number of therapeutic antibodies have been used for cell surface receptor blockage, interfering with the ligand binding and inhibiting receptor-driven activation of cells. Here we describe the construction and characterization of a recombinant bivalent single-chain Fv (biscFv) that targets CD123. On conversion of anti-CD123 scFv to biscFv format, the recognition of the cognate ligand is not altered. Moreover, the increased overall efficacy of the anti-CD123 biscFv in binding and inhibition of CD123/IL-3 (interleukin-3) interactions in TF-1 cells is demonstrated. |
| |
Keywords: | Antibody engineering AML Leukemic cancer stem cells Bivalent scFv (biscFv) CD123 |
本文献已被 ScienceDirect 等数据库收录! |
|